Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer

Conditions

• Metastatic Malignant Neoplasm

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Palliative Radiation Therapy — RADIATION
  Undergo palliative RT
• Quality-of-Life Assessment — OTHER
  Ancillary studies
• Questionnaire Administration — OTHER
  Ancillary studies
• Stereotactic Body Radiation Therapy — RADIATION
  Undergo SBRT

Study Details

This phase II trial studies how well single-fraction stereotactic body radiation therapy (SBRT) works when compared to standard radiation therapy in treating patients with cancer that has spread to other places in the body (metastatic). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.

Key Dates

Start date

Nov 18, 2019

Status verified

Apr 2026

Primary completion

Nov 18, 2027

Completion

Nov 18, 2027

Study Design

Enrollment

1,500 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Arm I (palliative RT)
  Patients undergo 1, 3-5, 5-6, or 10 fractions of palliative RT deemed appropriate by the treating physician.
• Experimental: Arm II (SBRT)
  Patients undergo single fraction SBRT.

Primary Outcome Measure

Pain responses [ Time Frame: Baseline up to 12 weeks ]

Locations (3)

Find similar trials in Buffalo, NY

Related Studies

• A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
  PHASE1 · Recruiting · NextPoint Therapeutics, Inc. · Baltimore, Maryland
• NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
  PHASE1 · Not Yet Recruiting · NextPoint Therapeutics, Inc. · La Jolla, California